Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2005

View Archived Issues

FK-228 investigated in phase I and phase II oncology trials

Study data reveal efficacy of zileuton in moderate to severe asthma

Altachem updates restructuring progress

Enrollment completed in phase IIb study of valopicitabine for hepatitis C

Biovitrum and Karolinska Institutet collaborate on inflammation research

Renovis and Pfizer establish VR1 antagonist collaboration

Phase I/II prostate cancer study of SPI-153 gets green light

4SC receives funding to develop new MS drug candidates

Tarvacin cleared to enter phase I study for HCV

New treatments claimed for Alzheimer's disease and other neurological disorders

Toxicity studies commence with ARQ-197

Phase I trial for Novagali's oral formulation of paclitaxel

Fast track designation for Riquent

First stage completed in phase IIa study of ATL-104 for mucositis

BioXell signs TREM development agreement with Merck

IND approval for cholesterol drug MAHDL-01

Phase I data on the immunogenicity and safety of the AMA1-C1 malaria vaccine

AD-237 reported safe and effective in improving lung function of COPD patients

A new clinical trial to assess the benefits of tolvaptan in heart failure / News in Context

Recent patents describe novel treatments for osteoporosis

NitroMed reports novel agents for treating cardiovascular diseases

Good safety and immunogenicity results reported for the Shigella vaccine CVD-1208S

FDA approval for Naglazyme

Update on sitaxsentan in pulmonary arterial hypertension

New phase I data on the effects and safety of ChimeriVax-West Nile vaccine

Promising alternative to gemcitabine offered by 4-thio-FAC

Enbrel approved to improve physical function in psoriatic arthritis

Derivatives of human embryonic stem cells offer potential for recovery after spinal cord injury

Prous Science's LifeSciChannel.com webcasts the AUA 2005 Annual Meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...